High-Flow Nasal Oxygen Noninferior to Noninvasive Ventilation for Acute Respiratory Failure

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 16, 2024.

By Lori Solomon HealthDay Reporter

MONDAY, Dec. 16, 2024 -- High-flow nasal oxygen (HFNO) is noninferior to noninvasive ventilation (NIV) for endotracheal intubation or death within seven days for most patients with acute respiratory failure, according to a study published online Dec. 10 in the Journal of the American Medical Association to coincide with the Critical Care Reviews Down Under meeting, held from Dec. 10 to 11 in Melbourne, Australia.

Israel S. Maia, M.D., Ph.D., from the HCor Research Institute in São Paulo, Brazil, and colleagues assessed whether HFNO is noninferior to NIV on the rates of endotracheal intubation or death at seven days. The researchers randomly assigned 1,766 hospitalized patients with acute respiratory failure (classified into five groups) to HFNO (883 patients) or NIV (883 patients).

The researchers found that the primary outcome of endotracheal intubation or death within seven days occurred in 39 percent in the HFNO group versus 38 percent in the NIV group overall. The primary outcome occurred at the following rates in the immunocompromised patient group with hypoxemia: 57.1 percent in the HFNO group versus 36.4 percent in the NIV group, with enrollment stopped for futility. The corresponding rates were 32.5 versus 33.1 percent in the nonimmunocompromised group with hypoxemia; 10.3 versus 21.3 percent in the acute cardiogenic pulmonary edema group; 51.3 versus 47.0 percent in the hypoxemic COVID-19 group; and 28.6 versus 26.2 percent in the group with chronic obstructive pulmonary disease exacerbation with respiratory acidosis. The incidence of serious adverse events was similar between the groups (HFNO: 9.4 percent; NIV: 9.9 percent).

"The small sample sizes in some patient groups and the sensitivity of the findings to the choice of analysis model suggests the need for further study in patients with chronic obstructive pulmonary disease, immunocompromised patients, and patients with acute cardiogenic pulmonary edema," the authors write.

One author disclosed ties to Roche Diagnostics, Novartis, and Bayer.

Abstract/Full Text

Editorial

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-12-17 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords